AVXL vs DYN
AVXL: A clinical-stage biopharma company developing precision medicine treatments for Alzheimer's, Parkinson's, and rare CNS diseases by targeting the sigma-1 receptor. DYN: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform.
Side-by-side fundamentals
| Metric | AVXL | DYN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.50 | $25.18 | |
| Market cap as of 2026-08-03 | $232M | $4.7B | |
| ROE as of 2026-08-03 | -38.8% | -58.3% | AVXL higher |
| ROA as of 2026-08-03 | -35.0% | -46.8% | AVXL higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.18 | AVXL lower |
| Beta as of 2026-08-03 | 1.15 | 1.79 | |
| 1-year return as of 2026-07-27 close | -79.4% | +155.6% | DYN higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.